Wall Street Cuts Mosaic Again: UBS Slashes Target to $27
UBS cuts Mosaic’s price target to $27, citing squeezed phosphate margins from higher sulfur and input costs, as Wall ...
Why Index Funds Offer More Control Than Target Date
Index funds generally provide more control over allocations than target date funds, which automate drift. This intro explains what that means in practice.
28,480 articles
Case for Holding VO in Your Roth IRA
As markets stabilize in 2026, a growing argument centers on placing the Vanguard Mid-Cap ETF (VO) inside a Roth IRA t...
Xcel Energy Could Year-End Rally as UBS Sees Value
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...
Here Monday’s Best Wall Street Calls Shape Markets
As the quarter winds down, Monday’s best Wall Street calls set the tone, spotlighting tech, energy and consumer names...
Billionaire Stanley Druckenmiller Dumped Four AI Stocks, Quadrupled Stake in Mega Cap
When a legendary investor shifts big positions, traders sit up. This piece breaks down what it could mean that billio...
K-Shaped Economy: Middle Class Crunch and Loan Strategies
The economy isn’t one size fits all. While stock markets soar, the middle class often feels squeezed. This guide expl...
XXRP’s Wipeout Reveals the Leverage Trap Investors Miss
A sharp Friday drop in the Teucrium 2x Long Daily XRP ETF underscores how daily-reset leverage can amplify losses in ...
FEMA Told These Families They Were Safe, Then Floods Hit
Northern Michigan families learned a hard lesson: being outside a flood zone on paper did not protect homes from a sp...
Northwestern Mutual 2025 Study: Millennial Inheritance Gap
A new northwestern mutual 2025 study exposes a sharp mismatch: Millennials prize wealth transfer yet most have not se...
Tempus AI Posts Revenue Growth, Misses Profit Target
Tempus AI reported an 83% jump in Q4 revenue to $367 million but failed to hit positive full-year profitability, guid...
Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Stock Market Today, June: Payoneer Acquisition Sparks Rally
On a June trading day, Payoneer Global surged on takeover chatter, highlighting how M&A rumors can move fintech names...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status